Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer-Reference-Cited by-同舟云学术

Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer

Published:2020-05-14 Issue:11 Volume:133 Page:1304-1311
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Wu Peng-Fei,Gao Wei-Wei,Sun Cui-Lan,Ma Tai,Hao Ji-Qing

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference38 articles.

1. Emerging new agents for the management of patients with non-small cell lung cancer;Capelletto;Drugs,2012

2. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation–diversity, ductility, and destiny;Suda;Cancer Metastasis Rev,2012

3. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma;Ramakrishnan;BMC Cancer,2016

4. Mechanisms underlying acquired resistance to tyrosine kinase inhibitors in lung cancer;Simasi;Pneumologie,2010

5. Will histone deacetylase inhibitors require combination with other agents to fulfill their therapeutic potential?;Nolan;Br J Cancer,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer;Frontiers in Pharmacology;2024-04-12

2. Histone deacetylases modulate resistance to the therapy in lung cancer;Frontiers in Genetics;2022-10-03

3. Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1;Cell Death Discovery;2022-10-01

4. Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers;Frontiers in Cell and Developmental Biology;2021-07-21

5. Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy;Seminars in Cancer Biology;2021-07